Pursuing AbbVie and J&J, Innovent hits primary endpoint in phase 2 psoriasis trial

[cafead]

via Innovent Biologics’ challenger to drugs including Johnson & Johnson’s Tremfya and AbbVie’s Skyrizi has cleared phase 2. The study found the anti-IL-23 monoclonal antibody, which is designed to be given less frequently than some rivals, outperformed placebo in terms of reducing psoriasis area and severity.

article source